Healthcare AI Expert Parminder Bhatia Joins Helio Genomics Board
Helio Genomics, a company focused on AI-driven liver diagnostics, has appointed Parminder Bhatia to its Board of Directors. Bhatia brings extensive experience in responsible AI deployment within regulated healthcare environments.
IRVINE, Calif. – Helio Genomics, Inc., a commercial-stage AI-powered precision diagnostics company for liver health, announced the appointment of Parminder (Parry) Bhatia, Senior Vice President of Artificial Intelligence at Edwards Lifesciences, to its Board of Directors. The company focuses on improving patient outcomes through early cancer detection.
Bhatia brings deep expertise in the responsible deployment of AI within regulated healthcare settings. Previously, he served as Chief AI Officer at GE HealthCare, where he accelerated the company's AI strategy across medical devices and software products. His prior roles include AI and machine learning positions at Amazon, Microsoft, and Georgia Tech.
"Parminder's leadership in healthcare AI and responsible innovation will be invaluable as Helio scales its platform to detect cancer earlier and improve outcomes for patients worldwide," said Dr. Bharat Tewarie, Chief Executive Officer of Helio Genomics. "His strategic perspective will strengthen our governance and support sustained, long-term value creation."
Helio Genomics is a commercial-stage company developing an AI-powered platform for early cancer detection and monitoring of minimal residual disease. The company utilizes machine learning to identify cancer biomarkers in blood tests.